We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cel Sci Corporation New | AMEX:CVM | AMEX | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.035 | -2.43% | 1.405 | 1.44 | 1.40 | 1.43 | 38,680 | 15:14:16 |
From May 2019 to May 2024
CEL-SCI Corporation (NYSE MKT: CVM), a Phase 3 cancer immunotherapy company, today announced that its Chief Executive Officer, Geert Kersten, will present at the NobleCon12 - Noble Financial Capital Markets’ Twelfth Annual Investor Conference at Club Med in Sandpiper Bay, Florida, on Tuesday, January 19th at 3:00 p.m. Eastern Standard Time.
Following the Conference on January 22, 2016, a video webcast of CEL-SCI’s presentation will be available on the Company's web site www.cel-sci.com/investor_relations.html, or as part of a complete catalog of presentations available at Noble Financial websites: www.noblefcm.com, or www.nobleconference.com. The webcast and presentation will be archived on the Company's website and on the Noble websites for 90 days following the event.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Over 668 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.
The Company has operations in Vienna, Virginia, and in/near Baltimore, Maryland.
About Noble Financial Capital Markets
Noble Financial Capital Markets established in 1984, is an equity-research driven, full-service, investment & merchant banking boutique focused on the healthcare, media & entertainment, technology and natural resources sectors. The company has offices in Boca Raton, New York, Boston and Los Angeles. In addition to the annual multi-sector NobleCon, each year Noble hosts numerous “non-deal” corporate road shows and sector-specific conferences. Members: FINRA, SIPC, MSRB. www.noblefcm.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160114005637/en/
CEL-SCI CorporationGavin de Windt, 703-506-9460
1 Year Cel Sci Chart |
1 Month Cel Sci Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
